Zydus Cadila's Covid vaccine in the inoculation drive and prioritising beneficiaries focusing on those aged 12-18 years with comorbidities.
The indigenously developed world's first DNA-based needle-free COVID-19 vaccine ZyCoV-D received Emergency Use Authorisation from the drug regulator on August 20 making it the first vaccine to be administered in the age group of 12-18 years in the country.
NTAGI Chairman Dr N K Arora said it is estimated that there are around 12 crore adolescents in the age group of 12-18 years in India and less than 1 per cent of them may have comorbidities. "The NTAGI's meeting will be held soon to chalk out a roadmap for introducing the three-dose ZyCoV-D vaccine in the ongoing COVID-19 vaccination drive.